241 related articles for article (PubMed ID: 25554623)
1. Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings.
Levin R; Dor-Abarbanel AE; Edelman S; Durrant AR; Hashimoto K; Javitt DC; Heresco-Levy U
J Psychiatr Res; 2015 Feb; 61():188-95. PubMed ID: 25554623
[TBL] [Abstract][Full Text] [Related]
2. Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder.
Heresco-Levy U; Vass A; Bloch B; Wolosker H; Dumin E; Balan L; Deutsch L; Kremer I
Int J Neuropsychopharmacol; 2009 Oct; 12(9):1275-82. PubMed ID: 19366490
[TBL] [Abstract][Full Text] [Related]
3. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
[TBL] [Abstract][Full Text] [Related]
4. Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors.
Labrie V; Clapcote SJ; Roder JC
Pharmacol Biochem Behav; 2009 Feb; 91(4):610-20. PubMed ID: 18940194
[TBL] [Abstract][Full Text] [Related]
5. Timing-dependent reduction in ethanol sedation and drinking preference by NMDA receptor co-agonist d-serine.
Lockridge A; Romero G; Harrington J; Newland B; Gong Z; Cameron A; Yuan LL
Alcohol; 2012 Jun; 46(4):389-400. PubMed ID: 22445805
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
7. Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
Heresco-Levy U; Shoham S; Javitt DC
Mov Disord; 2013 Apr; 28(4):419-24. PubMed ID: 23427107
[TBL] [Abstract][Full Text] [Related]
8. Age-related effects of the neuromodulator D-serine on neurotransmission and synaptic potentiation in the CA1 hippocampal area of the rat.
Junjaud G; Rouaud E; Turpin F; Mothet JP; Billard JM
J Neurochem; 2006 Aug; 98(4):1159-66. PubMed ID: 16790028
[TBL] [Abstract][Full Text] [Related]
9. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients.
Heresco-Levy U; Bar G; Levin R; Ermilov M; Ebstein RP; Javitt DC
Schizophr Res; 2007 Mar; 91(1-3):14-21. PubMed ID: 17276036
[TBL] [Abstract][Full Text] [Related]
10. The effect of D-serine administration on cognition and mood in older adults.
Avellar M; Scoriels L; Madeira C; Vargas-Lopes C; Marques P; Dantas C; Manhães AC; Leite H; Panizzutti R
Oncotarget; 2016 Mar; 7(11):11881-8. PubMed ID: 26933803
[TBL] [Abstract][Full Text] [Related]
11. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
Kantrowitz JT; Epstein ML; Beggel O; Rohrig S; Lehrfeld JM; Revheim N; Lehrfeld NP; Reep J; Parker E; Silipo G; Ahissar M; Javitt DC
Brain; 2016 Dec; 139(Pt 12):3281-3295. PubMed ID: 27913408
[TBL] [Abstract][Full Text] [Related]
12. Time and space profiling of NMDA receptor co-agonist functions.
Mothet JP; Le Bail M; Billard JM
J Neurochem; 2015 Oct; 135(2):210-25. PubMed ID: 26088787
[TBL] [Abstract][Full Text] [Related]
13. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
Labrie V; Roder JC
Neurosci Biobehav Rev; 2010 Mar; 34(3):351-72. PubMed ID: 19695284
[TBL] [Abstract][Full Text] [Related]
14. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
[TBL] [Abstract][Full Text] [Related]
15. The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls.
Palmer C; Ellis KA; O'Neill BV; Croft RJ; Leung S; Oliver C; Wesnes KA; Nathan PJ
Hum Psychopharmacol; 2008 Mar; 23(2):151-9. PubMed ID: 17972276
[TBL] [Abstract][Full Text] [Related]
16. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.
Heresco-Levy U; Javitt DC; Gelfin Y; Gorelik E; Bar M; Blanaru M; Kremer I
J Affect Disord; 2006 Jul; 93(1-3):239-43. PubMed ID: 16677714
[TBL] [Abstract][Full Text] [Related]
17. D-Serine differently modulates NMDA receptor function in rat CA1 hippocampal pyramidal cells and interneurons.
Martina M; Krasteniakov NV; Bergeron R
J Physiol; 2003 Apr; 548(Pt 2):411-23. PubMed ID: 12611916
[TBL] [Abstract][Full Text] [Related]
18. Astroglial d-serine is the endogenous co-agonist at the presynaptic NMDA receptor in rat entorhinal cortex.
Lench AM; Massey PV; Pollegioni L; Woodhall GL; Jones RS
Neuropharmacology; 2014 Aug; 83():118-27. PubMed ID: 24747728
[TBL] [Abstract][Full Text] [Related]
19. The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans.
Onur OA; Schlaepfer TE; Kukolja J; Bauer A; Jeung H; Patin A; Otte DM; Shah NJ; Maier W; Kendrick KM; Fink GR; Hurlemann R
Biol Psychiatry; 2010 Jun; 67(12):1205-11. PubMed ID: 20303474
[TBL] [Abstract][Full Text] [Related]
20. Glutamate as a therapeutic target in psychiatric disorders.
Javitt DC
Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
